Multicenter clinical trials to determine the efficacy and safety of consolidation and maintenance therapy with ixazomib, lenalidomide, dexamethasone (IRd) therapy in patients with multiple myeloma after autologous stem cell transplantation.

Multicenter clinical trials to determine the efficacy and safety of consolidation and maintenance therapy with ixazomib, lenalidomide, dexamethasone (IRd) therapy in patients with multiple myeloma after autologous stem cell transplantation. - prospective trial of ixazomib, lenalidomide, dexamethasone (IRd) therapy in patients with multiple myeloma after autologous stem cell transplantation.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032674

Enrollment

Registered

2018-06-01

Start date

2018-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory multiple myeloma

Interventions

The patients are treated with ixazomib (Day1, 8, 15) and lenalidomide (Day1-21) and dexamethasone (Day1, 8, 15, 22) therapy every 28 day cycle for 1 year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 MM patients with PR, VGPR, CR 2 with consent 3 measureble M-protein 4 PS 0-2 5 contraceptive

Exclusion criteria

Exclusion criteria: 1 relapsed myeloma 2 previous treatment history of ixazomib 3 treatment history of some drugs after auto SCT. 4 not tolerable to lenalidomide, bortezomib, dexamethasone 5 with Grade 2 or higher peripheral neuropathy 6 pregnancy 7 Abnormality of blood test 8 CNS involvement 9 Plasma cell leukemia 10 with severe infection 11 with intestinal pneumoniae 12 with double and more cancer 13 without consent of blood transfusion 14 and other

Design outcomes

Primary

Measure	Time frame
The rate of stringent CR achievemnt during the IRd therapy.	—

Secondary

Measure	Time frame
1 Time to sCR achievement period 2 MRD negativity achievement rate 3 ORR 4 Safety 5 PFS 6 OS 7 pharmacokinetics of lenalidomide, ixazomib	—

Countries

Japan

Contacts

Public ContactTakahiro Kobayashi

Akita University Graduate School of Medicine Department of Hematology, Nephrology, Rheumatology,

takahiro@med.akita-u.ac.jp018846116

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026